F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma
- 15 August 2001
- Vol. 92 (4) , 886-895
- https://doi.org/10.1002/1097-0142(20010815)92:4<886::aid-cncr1397>3.0.co;2-v
Abstract
Successful treatment of nonsmall cell lung carcinoma (NSCLC) with radical radiotherapy (RT) requires accurate delineation of tumor extent. Conventional computed tomography–based noninvasive staging often estimates intrathoracic thoracic tumor extent incorrectly and fails to detect distant metastasis. High sensitivity and specificity are reported for F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) staging in potentially resectable NSCLC. The authors investigated FDG-PET staging in radical RT candidates with unresectable NSCLC. The authors prospectively studied 153 consecutive patients with unresectable NSCLC who were candidates for radical RT after conventional staging and had PET scans. Patients were allocated both “before PET” and “after PET” stages. Subsequent management was recorded. Survival analysis was used to compare validity of pre-PET and post-PET staging. After PET, 107 patients (70%) actually received radical therapies (radical RT with or without concurrent chemotherapy, n = 102; radical surgery, n = 5); 46 patients (30%) received palliative treatment because of PET-detected distant metastasis (n = 28; 18%) or extensive locoregional disease (n = 18; 12%). Palliative therapies were RT (n = 33), chemotherapy (n = 12), or supportive care (n = 1). All five surgically treated patients underwent potentially curative resections after downstaging by PET. For radically treated patients, post-PET stage (P = 0.0041) but not pre-PET stage (P = 0.19) was strongly associated with survival. Radically treated patients survived longer than those treated palliatively (P = 0.02; 1-year survival, 69% and 44%, respectively; 2-year survival, 44% radical; no palliative patients had 2-yr follow-up). Positron emission tomography–assisted staging detected unsuspected metastasis in 20%, strongly influenced choice of treatment strategy, frequently impacted RT planning, and was a powerful predictor of survival. Potential impact of FDG-PET is even greater in radical RT candidates with NSCLC than in surgical candidates. Cancer 2001;92:886–95. © 2001 American Cancer Society.Keywords
This publication has 26 references indexed in Scilit:
- Metastases from Non-Small Cell Lung Cancer: Mediastinal Staging in the 1990s—Meta-analytic Comparison Of PET and CTRadiology, 1999
- Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 1998
- Detection of extrathoracic metastases by positron emission tomography in lung cancerThe Annals of Thoracic Surgery, 1998
- Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients.Journal of Clinical Oncology, 1998
- Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography.American Journal of Roentgenology, 1997
- Positron emission tomography in the clinical evaluation of metastatic cancer.Journal of Clinical Oncology, 1996
- Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancerThe Lancet, 1994
- Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucoseThe Annals of Thoracic Surgery, 1994
- Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling.Radiology, 1992
- CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group.Radiology, 1991